AGE-1 Glucose modifiedCatalogue number: AGE1-010
Glukose-modified AGEs (AGE-1) induce Apoptosis and Micro-albuminuria by destruction of mesangial cells of the human kidney. In this way they are responsible for the onset of early diabetic nephropathy. The antibody is well suited for the detection of AGE-1 in tissue extracts body fluids and cell culture media. Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) ß2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimer’s disease. These results suggested the potential role of AGE in normal aging and age-enhanced disease processes. Glukose modified AGE, in Western Blot no cross-reaction with AGE-2 (Glyceraldehyde modified), AGE-3 (Glycolaldehyde modified), AGE-4 (Methylglyoxal-modified), AGE-5 (Glyoxal-modied), AGE-6 (3-DG-modified), CEL-BSA, CML-BSA and BSA..
Protein G affinity purified monoclonal antibody in PBS with 2% Block Ace as stabilizer and 0.1% Proclin as preservative
Purification Method: Protein G affinity purified monoclonal antibody in PBS with 2% Block Ace as stabilizer and 0.1% Proclin as preservative
Concentration: 0.25 mg/ml
Secondary Reagents: As secondary system in ELISA and Western Blot we recommend biotinylated anti-mouse IgG antibody (Art. No. ZU102) in combination with streptavidin-HRPO conjugate (Art. No. ZU054) or streptavidin-alkaline phosphatase (Art. No. ZU051).
Species Reactivity: Human
Incubation Time: 60 min at RT or 18 hr at 2-8°C
Working Concentration: (liquid conc.) 0,1 µg/ml (WB and ELISA)
Positive Control: human lens, arteriosclerotic plaques
These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.
1. Takeuchi M. , Makita Z., Bucala R., Suzuki T., Koike T., and Kameda Y. (2000) Immunological evidence that non-carboxymethyllysine Advanced Glycation End-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol. Med. 6; 114-125. 2. Takeuchi M., Yanase Y., Matsuura N., Yamagishi S., Kameda Y., Bucala R., and Z. Matika (2001) Immunological detection of a novel Advanced Glycation End-Product. Mol. Med. 7; 783-791. 3. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., and Makita Z. (2002) Advanced Glycation End Products-Induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor in Bovine Retinal Pericytes Biochemical and Biophysical Research Communications ; 290, 973-978.
AGE-1 Glucose modified